Objectives: To evaluate the presence of type-specific human papillomavirus (HPV) DNA in atypical glandular cells (AGCs) from cervical liquid-based cytology and to report the relationship between HPV types and cervical histological abnormalities. Study Design: We used a nested multiplex polymerase chain reaction assay to test AGC Papanicolaou (Pap) tests for the presence of 14 high-risk (HR) HPV types. Results: HR HPV types were detected in 33 of 161 AGC Pap tests (20.3%). Types 16 and/or 18 were detected in 13 samples (8%). Eight other HPV types were detected in 1–4 samples each. HPV-associated disease was diagnosed in 8 AGC cases (8%) with available histology results. The sensitivity and specificity of the HR HPV test were 87.5 and 90%, respectively, and the negative predictive value (NPV) was 99%. For a test that can isolate HPV types 16 and 18, the sensitivity and specificity were 62.5 and 100%, respectively, the positive predictive value (PPV) was 100% and the NPV was 97%. Conclusion: HPV 16 and 18 were the most common types detected in AGC Paps. We found high specificity, PPV and NPV with a test that can isolate these 2 HPV types. These results indicate a possible role for type-specific HPV testing in the management of AGC Pap tests.

Keywords:
Atypical glandular cells, Human papillomavirus, Pap test
1.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
2.
Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference: 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120–2129.
3.
Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201–222.
4.
Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N; Forum Group Members; Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
5.
Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Menton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bültmann B: Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol 2004;42:3176–3184.
6.
Schnatz PF, Sharpless KE, O’Sullivan DM: Use of human papillomavirus testing in the management of atypical glandular cells. J Low Genit Tract Dis 2009;13:94–101.
7.
Derchain SF, Rabelo-Santos SH, Sarian LO, Zeferino LC, de Oliveira Zambeli ER, do Amaral Westin MC, de Angelo Andrade LA, Syrjänen KJ: Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 2004;95:618–623.
8.
Diaz-Montes TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL: Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol 2007;104:366–371.
9.
de Oliveira ER, Derchain SF, Sarian LO, Rabelo-Santos SH, Gontijo RC, Yoshida A, Andrade LA, Zeferino LC: Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer 2006;16:1055–1062.
10.
Saqi A, Gupta PK, Erroll M, Babiac A, Blackmun D, Mansukhani M, Vazquez M: High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol 2006;34:235–239.
11.
Irvin W, Evans SR, Andersen W, Jazaeri A, Taylor P, Stoler M, Pastore L, Rice L: The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol 2005;193:559–565, discussion 565–567.
12.
Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WK, Hurley LB, Ngai JS, Kurman RJ, Sherman ME: Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999;30:816–825.
13.
Chen SF, Yang SF, Chu TY, Lai HC, Lin YW, Bai CY, Nieh S: Which test is a better strategy to determine the outcome of atypical glandular cell-categorized Pap smears? Immunocytochemical p16INK4A expression or human papillomavirus test – a retrospective cohort study. Gynecol Oncol 2005;99:578–584.
14.
Sharpless KE, O’Sullivan DM, Schnatz PF: The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. J Low Genit Tract Dis 2009;13:72–78.
15.
Lee KR, Darragh TM, Joste NE, Krane JF, Sherman ME, Hurley LB, Allred EM, Manos MM: Atypical glandular cells of undetermined significance (AGUS): interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol 2002;117:96–102.
16.
Moreira MA, Longatto Filho A, Castelo A, de Barros MR, Silva AP, Thomann P, Mattosinho de Castro Ferraz Mda G, Dores GB: How accurate is cytological diagnosis of cervical glandular lesions? Diagn Cytopathol 2008;36:270–274.
17.
Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol 2005;105:501–506.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.